<DOC>
	<DOCNO>NCT01543659</DOCNO>
	<brief_summary>The purpose study define safety accuracy 89Zr-DFO-huJ591 PET scan . By improve ability find cancer cell , investigator hope able improve treatment patient future . The study doctor want determine whether new kind scan , call 89Zr-DFO-huJ591 PET scan , specifically see prostate cancer spread part body , especially bone . The study doctor also look 89Zr-DFO-huJ591 reacts body long stay body . The investigator also ask patient biopsy perform . The study doctor compare finding investigator see scans finding optional tissue biopsy . Finally , investigator compare picture 89Zr-DFO-huJ591 PET scan standard PET scan ( call FDG PET ) standard CT scan magnetic resonance ( MRI ) scan bone scan , depend standard scan doctor order . PET scan us small amount radiation attach molecule take cancer . In trial , patient undergo two type PET scan . One use FDG . FDG standard tracer PET scan . The patient also undergo another type PET scan experimental . This experimental PET use radioactive protein call J591 . The radiation source type metal call zirconium-89 ( 89Zr ) . The whole tracer , J591 plus 89Zr , abbreviate 89Zr-DFO-huJ591 . This tracer study . The tracer use scan find cancer body .</brief_summary>
	<brief_title>Clinical Molecular Correlates Positron Emission Tomography ( PET ) With 89Zr-DFO-huJ591 Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Metastatic Prostate Cancer Patients : Adult male ≥ 18 year age Patients histologically confirm prostate cancer MSKCC Progressive disease manifest either : Imaging modality : Bone Scan : New osseous lesion bone scan and/or MRI CT : An increase measurable soft tissue disease appearance new site disease . OR Biochemical progression : At least 3 rise PSA value baseline obtain 1 week apart , 2 measurement obtain 2 week apart . The increase range value least 25 % . Visible lesion CT , bone scan , MRI consistent disease Performance status 60 high ( Karnofsky scale ) ( Appendix B ) Ability understand willingness sign write informed consent document Rising PSA Prostate Cancer Patients : Adult male ≥18 year age Patients histologically confirm prostate cancer MSKCC Undergone radical prostatectomy Detectable PSA ( &gt; 0.05 ng/mL ) rise subsequent evaluation Radiographic evaluation involve bone image cross sectional imaging least pelvis negative equivocal metastatic disease Performance status 60 high ( Karnofsky scale ) ( Appendix B ) Ability understand willingness sign write informed consent document Patients meeting follow criterion eligible study entry ( Metastatic Rising PSA cohort ) : Previous anaphylactic reaction either J591 FDG Hepatic laboratory value Bilirubin &gt; 1.5 x ULN ( institutional upper limit normal ) Exception : patient 's history Gilbert 's disease AST/ALT &gt; 2.5 x ULN Albumin &lt; 2 g/dL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>89Zr-DFO-huJ591</keyword>
	<keyword>prostate</keyword>
	<keyword>Pet scan</keyword>
	<keyword>11-126</keyword>
</DOC>